S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
S&P 500   3,948.72 (+0.30%)
DOW   32,105.25 (+0.23%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:OCX

OncoCyte - OCX Stock Forecast, Price & News

$0.23
-0.01 (-4.13%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.22
$0.27
50-Day Range
$0.20
$0.49
52-Week Range
$0.20
$1.68
Volume
649,228 shs
Average Volume
428,151 shs
Market Capitalization
$27.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.35

OncoCyte MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
482.1% Upside
$1.35 Price Target
Short Interest
Healthy
0.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.39) to ($0.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

301st out of 986 stocks

Diagnostic Substances Industry

5th out of 14 stocks


OCX stock logo

About OncoCyte (NASDAQ:OCX) Stock

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Oncocyte Completes Razor Genomics Transaction
Oncocyte Announces Initiatives to Focus Corporate Strategy
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Oncocyte Announces Executive Leadership Changes
OncoCyte (OCX) Reports Q3 Loss, Misses Revenue Estimates
Oncocyte Reports Third Quarter 2022 Financial Results
Oncocyte to Announce Third Quarter 2022 Financial Results
OncoCyte Corporation (OCX)
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Company Calendar

Last Earnings
11/09/2021
Today
3/23/2023
Next Earnings (Confirmed)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.35
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+450.6%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-64,100,000.00
Net Margins
-787.97%
Pretax Margin
-786.76%

Debt

Sales & Book Value

Annual Sales
$7.73 million
Book Value
$0.71 per share

Miscellaneous

Free Float
113,827,000
Market Cap
$29.09 million
Optionable
Optionable
Beta
1.70

Key Executives

  • Joshua Riggs
    President, Chief Executive Officer & Director
  • Anish John
    Chief Financial Officer & Senior Vice President
  • Ekkehard Schütz
    Chief Technology Officer
  • Mitchell Stuart Levine
    Corporate Development Officer
  • Padma Sundar
    Chief Commercial Officer













OCX Stock - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price forecast for 2023?

4 analysts have issued 12 month price objectives for OncoCyte's stock. Their OCX share price forecasts range from $0.50 to $3.00. On average, they predict the company's share price to reach $1.35 in the next twelve months. This suggests a possible upside of 450.6% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $0.3209 at the start of the year. Since then, OCX shares have decreased by 23.6% and is now trading at $0.2452.
View the best growth stocks for 2023 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our OCX earnings forecast
.

How can I listen to OncoCyte's earnings call?

OncoCyte will be holding an earnings conference call on Wednesday, March 29th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) posted its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The business earned $0.98 million during the quarter, compared to analysts' expectations of $3.20 million. OncoCyte had a negative trailing twelve-month return on equity of 54.99% and a negative net margin of 787.97%.

What other stocks do shareholders of OncoCyte own?
What is OncoCyte's stock symbol?

OncoCyte trades on the NASDAQ under the ticker symbol "OCX."

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a number of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (6.11%), Defender Capital LLC. (1.92%), Millennium Management LLC (0.47%), Schonfeld Strategic Advisors LLC (0.36%), Penbrook Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $0.25.

How much money does OncoCyte make?

OncoCyte (NASDAQ:OCX) has a market capitalization of $29.09 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact OncoCyte?

OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389.

This page (NASDAQ:OCX) was last updated on 3/23/2023 by MarketBeat.com Staff